Administrative information
Title {1} | SPIOMET4HEALTH – Efficacy, Tolerability and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) plus Lifestyle Intervention for Adolescent Girls and Young Women with Polycystic Ovary Syndrome: Study Protocol for a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Four-Arm Parallel Groups Clinical Trial |
Trial registration {2a and 2b} | EudraCT: 2021–003177-58 |
Protocol version {3} | Version 4.0; 15 November 2022 |
Funding {4} | The SPIOMET4HEALTH project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899671. The funding body had no role in the design of the study, in the collection, analysis and interpretation of data and in writing the manuscript |
Author details {5a} | 1Paediatric Endocrinology, Paediatric Research Institute Sant Joan de Déu, University of Barcelona, 08950 Esplugues, Barcelona, Spain 2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, 28029 Madrid, Spain 3Department of Gynaecology and Obstetrics and Department of Endocrinology, University of Southern Denmark, Odense University Hospital, Odense, Denmark 4Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey 5Maternal-Fetal Metabolic Research Group, Girona Institute for Biomedical Research (IDIBGI), Girona, Spain 6Department of Paediatric Endocrinology, Diabetes and Nutrition Medicine, Vestische Hospital for Children and Adolescents Datteln, University of Witten-Herdecke, Datteln, Germany 7Department of Medical and Surgical Science-DIMEC, Division of Endocrinology and Diabetes Prevention and Care, University of Bologna—S. Orsola-Hospital, Bologna, Italy 8Division of General Paediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria 9Paediatric Endocrinology Research Group, Girona Institute for Biomedical Research (IDIBGI); Paediatrics, Dr. Josep Trueta Hospital; and Department of Medical Sciences, University of Girona, Girona, Spain 10Asphalion, Barcelona, Spain 11Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 12Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway 13Centre for Obesity Research, St. Olavs Hospital, Trondheim University Hospital, Torgarden, Trondheim, Norway 14Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy 15Department of Obstetrics and Gynaecology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway 16Optimapharm, Palma de Mallorca, Spain 17Leuven Research & Development, University of Leuven, 3000 Leuven, Belgium |
Name and contact information for the trial sponsor {5b} | Fundació de Recerca Sant Joan de Déu Carrer de Santa Rosa 39–57 08950 Esplugues de Llobregat, Barcelona Spain |
Role of sponsor {5c} | The funding instance has no role in the study design, data collection, data analysis and interpretation, writing the report or decision to submit the report for publication. The Sponsor will act as recruiting partner and as the coordinator of the clinical trial |
Introduction
Background and rationale {6a}
Main targets
|
Side effects to be avoided
|
Efficacy with low doses
|
Safety concerns with low doses
| |
---|---|---|---|---|
SPI (50 mg/d) | Less androgen effect More BAT activity (CXCL14) | Hyperkalaemia | + | None |
PIO (7.5 mg/d) | Less hepatic fat More HMW-adip | Weight gain | + | None |
MET (850 mg/d) | Multiple mechanisms Less appetite (GDF15) | Abdominal discomfort | + | None |
SPIOMET | Improved metabolic health, including less ectopic fat and more ovulations | Safety concerns | + + + | None |
No need for a higher dose in order to augment efficacy
|
No need for a lower dose in order to reduce side effects
| |
---|---|---|
SPI (50 mg/d) | SPI is a BAT activator [45] Circulating concentrations of CXCL14, a marker of BAT activity, are low in adolescent girls with PCOS, and this low SPI dose is enough to raise circulating CXCL14 towards normal [74] | > 50 years of experience do not point to safety concerns with doses ≤ 1 mg/kg/d 50 mg/d is at the lower limit of the recommended range (50–200 mg/d) [14] |
PIO (7.5 mg/d) | HMW-adip is an adipokine with insulin-sensitising and anti-inflammatory properties Circulating concentrations of HMW-adip are low in adolescent girls with PCOS, and this low pioglitazone dose is enough to raise circulating HMW-adip towards normal concentrations, and even above normal [43] | > 25 years of experience do not point to safety concerns with a dose of 7.5 mg/d In adolescent girls with PCOS, a dose of 7.5 mg/d corresponds to approximately 0.1 mg/kg/d, whereas children are known to tolerate doses of 0.25, 0.50 and 0.75 mg/kg/d [58] |
MET (850 mg/d) | Circulating GDF15 has been unmasked as a key mediator of metformin effects [60] In adolescent girls with PCOS, a metformin dose of 850 mg/d is enough to raise circulating GDF15 nearly threefold above the levels in healthy controls [61] | 850 mg/d is at the lower limit of the recommended range (850–2000 mg/d) [14] EMA & FDA authorised the use of metformin in doses up to 2000 mg/d in children with type 2 diabetes |
Objectives {7}
Trial design {8}
Methods: participants, interventions and outcomes
Study setting {9}
Eligibility criteria {10}
Inclusion criteria
Exclusion criteria
Who will take informed consent? {26a}
Additional consent provisions for collection and use of participant data and biological specimens {26b}
Interventions
Explanation for the choice of comparators {6b}
-
The Placebo arm is required for key comparisons with SPIOMET arm.
-
The PIO arm allows to obtain hitherto scarce data with low-dose PIO in monotherapy in adolescent girls.
-
The SPIO arm offers low-dose SPI an opportunity to disclose its additional effects, on top of PIO.
Intervention description {11a}
Pioglitazone (7.5 mg)
|
Spironolactone (50 mg)
|
Metformin (850 mg)
|
Excipient
| |
---|---|---|---|---|
Arm 1 Placebo
| No | No | No | 1.1 g |
Arm 2 PIO
| Yes | No | No | Up to 1.1 g |
Arm 3 SPIO
| Yes | Yes | No | Up to 1.1 g |
Arm 4 SPIOMET
| Yes | Yes | Yes | Up to 1.1 g |
Criteria for discontinuing or modifying allocated interventions {11b}
Strategies to improve adherence to interventions {11c}
Relevant concomitant care permitted or prohibited during the trial {11d}
Provisions for post-trial care {30}
Outcomes {12}
Primary outcome
Secondary outcomes
-
Circulating androgens: total testosterone, SHBG, FAI (equivalent to free testosterone), and androstenedione
-
Lipids—total cholesterol, low-density lipoprotein (LDL-cholesterol), high-density lipoprotein (HDL-cholesterol), triglycerides
-
Insulinaemia: fasting and 2 h after an oral glucose load [oral glucose tolerance test (OGTT)]. Estimation of insulin resistance from fasting insulin and glucose levels using the insulin resistance homeostatic model assessment (HOMA-IR)
-
Markers of inflammation and insulin sensitivity: us-CRP, C-X-C motif chemokine ligand-14 (CXCL14), HMW-adip, GDF15
-
Cardiovascular risk: cIMT (ultrasound)
-
Body composition: dual-energy X-ray absorptiometry (DXA)
-
Abdominal fat distribution (subcutaneous and visceral) and hepatic fat (magnetic resonance imaging, MRI)
-
Laboratory safety variables: blood count (haemoglobin, haematocrit, red blood cell count, white blood cell count, platelet count), electrolyte panel (sodium, potassium, chloride, calcium, phosphorus), urea, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), creatinine, vitamin B12 and folic acid
-
Pregnancy test
-
Report of AEs
-
Adherence and acceptability:
-
Adherence, calculated as the ratio between the number of tablets prescribed and dispensed for the period between two hospital appointments and the number of tablets returned by the patient at the following appointment
-
Acceptability of the tablet by the study patients
Participant timeline {13}
Study months (± 2 weeks)
a
| ||||||||
---|---|---|---|---|---|---|---|---|
Timepoint
|
Screening
|
On-treatment
|
Post-treatment
| |||||
− 1
|
0
|
3
|
6
|
9
|
12
|
15
|
18
| |
Enrolment
| ||||||||
Eligibility screen “ | X | |||||||
Informed consent | X | |||||||
Medical history and prior medicationb
| X | |||||||
Randomisationc
| X | |||||||
Interventions
| ||||||||
Pharmacological intervention
| ||||||||
Placebo | X | X | X | X | X | |||
PIO | X | X | X | X | X | |||
SPIO | X | X | X | X | X | |||
SPIOMET | X | X | X | X | X | |||
Lifestyle intervention
d
| ||||||||
LIP and LIP-related questionnaires | X | X | X | X | X | |||
Assessments
| ||||||||
Ovulation assessment
e
| ||||||||
0–3 months—start | X | |||||||
0–3 months—stop | X | |||||||
9–12 months—start | X | |||||||
9–12 months—stop | X | |||||||
12–15 months—start | X | |||||||
12–15 months—stop | X | |||||||
Clinical variables
| ||||||||
Weight, height, BMI, WHR, SBP, DBPf
| X | X | X | X | X | X | X | |
Hirsutism score | X | X | X | X | X | X | X | |
Acne score | X | X | X | X | X | X | X | |
Menstrual regularity | X | X | X | X | X | X | X | |
Endocrine-metabolic variables
| ||||||||
Circulating androgensg
| X | X | X | X | ||||
Lipidsg
| X | X | X | X | ||||
Fasting insulin and glycaemiah
| X | Xh
| X | Xh
| X | Xh
| X | |
Glucose-stimulated insulinaemia (OGTT)i
| X | X | X | |||||
Markers of inflammation & insulin sensitivityg
| X | X | X | X | ||||
Epigenetic variables
| ||||||||
Circulating miR-451a concentrations | X | X | X | X | ||||
Imaging variables
j
| ||||||||
Cardiovascular risk: cIMT (ultrasound) | X | X | X | |||||
Body composition: DXA | X | X | X | |||||
Abdominal fat distribution and hepatic fat: MRI | X | X | X | |||||
Adherence and acceptability
| ||||||||
Adherence to treatment | X | X | X | X | X | |||
Acceptability of the tablet | X | X | ||||||
Safety variables
| ||||||||
Laboratory safety variablesk
| X | X | X | X | ||||
Pregnancy testl
| X | X | X | X | X | |||
Adverse events reportingm
| X | X | X | X | X | X | X | |
PROMs on HRQoL
n
| ||||||||
SF-36 | X | X | X | X | ||||
PCOSQ | X | X | X | X | ||||
Other activities
| ||||||||
Concomitant medicationo
| X | X | X | X | X | X | X | |
Patient diary | X | X | X | X | X | X | ||
Online survey (optional)p
| X | X |
Sample size {14}
Allocation ratio | 1:1:1:1 | |
---|---|---|
Sample size
| ||
Total
|
364
| |
Placebo | 91 | |
PIO | 91 | |
SPIO | 91 | |
SPIOMET | 91 | |
Minimal detectable mean differences
a
and common standard deviations
|
Power
b
| |
1. Placebo vs SPIOMET | 0.922 (1.96) | 80% |
2. Placebo vs SPIO | 0.922 (1.96) | 64% |
3. Placebo vs PIO | 0.922 (1.96) | 51% |
4. PIO vs SPIOMET | 0.922 (1.96) | 41% |
5. SPIO vs SPIOMET | 0.922 (1.96) | 33% |
Recruitment {15}
-
N = 70 at HSJD – FSJD (Spain)
-
N = 46 at Hospital de Girona Dr. Josep Trueta – IDIBGI (Spain)
-
N = 54 at Azienda Ospedaliero-Universitaria S. Orsola, di Bologna (UNIBO) (Italy)
-
N = 39 at Odense University Hospital—UNIODE (Denmark)
-
N = 41 at St. Olavs Hospital – NTNU (Norway)
-
N = 72 at Medical University of Graz (Austria)
-
N = 42 at Istanbul Faculty of Medicine Topkapi – ISTA (Turkey)
Assignment of interventions: allocation
Sequence generation {16a}
Concealment mechanism {16b}
Implementation {16c}
Assignment of interventions: blinding
Who will be blinded {17a}
Procedure for unblinding if needed {17b}
Data collection and management
Plans for collection and assessment of outcomes {18a}
Collection of outcomes
-
Study candidates will be recruited at the outpatient clinic of participating hospitals and written informed consent will be obtained. Medical history will be taken, including gynaecological age, menstrual regularity, clinically significant events over the past 5 years and the use of medication related to the PCOS phenotype and/or to the inclusion/exclusion criteria.
-
Confirmation of eligibility will require a clinical visit (hirsutism and acne scores; BMI) and blood sampling [to assess blood count, electrolyte panel, lipids, glucose, insulin, ALT, AST, GGT, creatinine, urea, vitamin B12, folic acid, progesterone, 17-OH-progesterone, thyroid-stimulating hormone (TSH), androgens (testosterone, SHBG, FAI, dehydroepiandrosterone-sulphate), prolactin, ultra-sensitive human chorionic gonadotropin (us-HCG)]. Androgens will be measured in the early follicular phase of the cycle (days 3 to 7) or after 2 months of amenorrhea.
-
Saliva samples for ovulation assessment (by progesterone measurement) will be collected weekly between 0 and 3 months (for 12 consecutive weeks during months 1, 2 and 3), between 9 and 12 months (for 12 weeks during months 10, 11 and 12) and between 12 and 15 months (for 12 weeks during months 13, 14 and 15).
-
Clinical features will be collected at each time point (height and weight to infer BMI; waist and hip circumference to infer WHR; SBP and DBP; hirsutism and acne scores; menstrual regularity) besides information on concomitant medication and adverse events.
-
At time 0, 6, 12 and 18 months, blood sampling will be performed in the fasting state to assess endocrine-metabolic, epigenetic and laboratory safety variables. At time 0, 12 and 18 months, additional blood sampling will be performed after 2 h of glucose upload for insulin and glycaemia assessment. At time 3, 9 and 15 months, blood sampling (for fasting insulin and glycaemia assessment) will be performed only in the event of clinically relevant hyperglycaemia observed at any time in the prior months.
-
At time 0, 12 and 18 months, ultrasound, DXA and MRI will be performed for assessments of respectively cIMT, body composition, and partitioning of abdominal fat, including hepatic fat.
-
Adherence to treatment will be assessed at each time point from baseline to time 12 months; whereas acceptability of the tablet will only be recorded at time 3 and 12 months.
-
A highly sensitive serum or standard sensitive urine pregnancy test will be performed at each time point from baseline to time 12 months.
-
At each time point from baseline to time 12 months, will attend to a LIP session, and fill in LIP-related questionnaires.
-
At time 0, 6, 12 and 18 months, PROMs on HRQoL will also be assessed.
-
Between hospital visits throughout the 18 months of study, the participants will record—in a diary—their menses, the time of any medication intake and any adverse event. Participants will deliver this diary at the next visit.
-
At time 0 and 18 months, an online survey will collect information on the patient’s experience, respectively, during the enrolment process and throughout the 18 months of the actual study.
Assessment of outcomes
-
measure height and weight to infer BMI
-
measure waist and hip circumference to infer WHR
-
measure SBP and DBP with an electronic sphygmomanometer on the right arm after a 5-min rest, with the participant supine
-
take a history including information about menstrual regularity and the intake of concomitant medication
-
Serum us-CRP levels will be measured by immuno-chemiluminescence at participating centres.
-
Circulating CXCL14 will be measured by a specific ELISA kit (RayBiotech, Nocross, GA, USA) with a sensitivity of 0.7 ng/mL, and with intra- and inter-assay CV < 12% (74).
-
Circulating GDF15 will be measured by a specific human ELISA kit (R&D Systems, Minneapolis, MN, USA) with intra- and inter-assay CVs < 6%, as reported [100].
-
Imaging parameters (by DXA, MRI and cIMT)
-
Clinical variables (including BMI)
-
Endocrine-metabolic variables (including lipids and usCRP)
-
Health behaviour assessed through a questionnaire on physical activity, eating behaviour and nutrition [questions adapted from HBSC questionnaire [102]]
-
Minimisation of adverse side effects, mainly aggravation of unfavourable eating behaviour [103] and evaluation of the risk of eating disorders assessed through the SCOFF and the first question of BEDS-7; only in case the risk is confirmed, then, the EDE-Q will be used which covers the four subscales of restraint, eating concerns, weight concern and shape concern [104].
-
Adherence to LIP (completion of session preparation task).
-
PROMS on HRQoL [generic (SF-36) and specific (PCOSQ) questionnaires (see below)].
Numerical Rating Scales (NRSS) OR qualitative/descriptive controlled vocabulary for palatability/acceptability assessments of paediatric oral use formulations | |||||
---|---|---|---|---|---|
Score
|
1
|
2
|
3
|
4
|
5
|
Overall opinion of taste | Very bad | Bad | Acceptable/ OK/ Not nice and not bad | Good/ Nice | Very good/ Very nice |
Overall swallowability (descriptive) | Vomits the drug immediately or within 2 h | Spat it out | Swallowed with some problems | Swallowed with no problems | |
Parent/caregivers’ overall opinion on their daughter’s acceptability of the formulation | Very bad | Bad | Acceptable/ OK | Good | Very good |
Plans to promote participant retention and complete follow-up {18b}
-
The clinical site (investigator or designee) will make a first attempt to contact the participant, will point to the importance of the study schedule and will make a new appointment at mutually earliest convenience, unless the participant clearly expresses the wish to abandon the study.
-
If a first attempt to contact the participant fails, then at least three further attempts will be made by phone, by certified letter to the participant’s last known mailing address, or by equivalent routes. These contact attempts will be documented in the participant’s medical record or study file.
-
If the participant cannot be reached by the staff of the study centre, or ends up skipping the next visit too, then she will be considered to have withdrawn from the study, due to loss of follow-up.
Data management {19}
-
Clinical and endocrine-metabolic data: numerical data obtained by the staff during the clinical visits or blood tests and collected through the eCRF.
-
Imaging data (DICOM): will be obtained by analysis of ultrasound, DXA and MRI data. All images will be sent electronically to an online repository (QUIBIM).
-
Information from patient diary and questionnaires (HBSC, SCOFF, BEDS-7, EDE-Q, SF-36, PCOSQ and acceptability of the tablet questionnaire) will be collected on paper and transcribed to the eCRF by the investigators or their designees.
Confidentiality {27}
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
Analysis of the primary outcome
Analysis of secondary outcomes
Interim analyses {21b}
Methods for additional analyses (e.g. subgroup analyses) {20b}
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}
Plans to give access to the full protocol, participant-level data and statistical code {31c}
Oversight and monitoring
Composition of the coordinating centre and trial steering committee {5d}
Composition of the data monitoring committee, its role and reporting structure {21a}
Adverse event reporting and harms {22}
Frequency and plans for auditing trial conduct {23}
Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}
Dissemination plans {31a}
-
Patients with PCOS and their families, including patient associations and general public (press release, informative talks, web, radio, television)
-
Clinicians, researchers and academic staff (articles in peer-reviewed journals, presentations at national and international meetings)